Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
EU Approves Linerixibat as First Ileal Bile Acid Transporter Inhibitor for PBC Itch

EU Approves Linerixibat as First Ileal Bile Acid Transporter Inhibitor for PBC Itch

November 20, 2026 Health Desk Health

The European Commission has approved linerixibat, sold as Lynavoy, for severe itching in adults with primary biliary cholangitis, the Commission decided at the end of October 2026.

The approval makes the drug the first ileal bile acid transporter inhibitor cleared for the condition in the European Union, Deutsche Apotheker Zeitung reported on November 19.

  • The European Commission approved linerixibat (Lynavoy) at the end of October 2026 for cholestatic pruritus in adults with primary biliary cholangitis.
  • The decision follows a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use in July 2026.
  • Linerixibat is the first ileal bile acid transporter inhibitor approved for this rare autoimmune liver disease, which affects a small patient population with few existing treatment options.

Primary biliary cholangitis is a rare autoimmune disease of the liver, Deutsche Apotheker Zeitung reported. Autoantibodies trigger chronic inflammatory damage to the bile ducts inside the liver. Over time, that damage can progress to liver necrosis or cirrhosis of the organ.

The symptom that weighs on many patients is intense itching, known medically as cholestatic pruritus. It is this symptom — not the underlying autoimmune process — that linerixibat is approved to treat. The drug’s indication covers cholestatic pruritus in adult patients with primary biliary cholangitis.

Linerixibat is an inhibitor of the ileal bile acid transporter, a protein that recycles bile acids from the intestine back into the bloodstream. Blocking that reabsorption is the mechanism behind the drug’s effect on cholestatic itch, Deutsche Apotheker Zeitung reported. The outlet described the approval as a first: no other ileal bile acid transporter inhibitor has been approved for this disease.

Treatment options for primary biliary cholangitis itself remain limited. Ursodeoxycholic acid, which promotes bile flow, is used to slow disease progression, Deutsche Apotheker Zeitung reported. A second class, agonists at peroxisome proliferator-activated receptors, known as PPAR agonists, is also in use. Neither class was developed specifically to relieve the itching that dominates many patients’ daily lives, which is the gap the new approval addresses.

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval in July 2026, Deutsche Apotheker Zeitung reported. The European Commission followed that recommendation with its decision at the end of October. The sequence — committee recommendation, then Commission decision — is the standard route to market authorization for medicines across the European Union.

The approval covers adults only. Children and adolescents are outside the authorized indication.

For adults with primary biliary cholangitis whose itching persists despite existing therapy, the decision adds a targeted pharmaceutical option where few existed. Patients and their treating physicians — hepatologists and gastroenterologists who manage chronic cholestatic liver disease — will weigh the new drug against the current standard of care on a case-by-case basis, since the approval defines the indication narrowly around pruritus rather than the underlying disease process.

The reporting did not include pricing, reimbursement decisions, or launch timing for individual EU member states, and Deutsche Apotheker Zeitung said that access details remain to be settled at the national level.


Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

More on this story: FDA Approves Bepirovirsen: The First Antisense Oligonucleotide Therapy for Chronic Hepatitis B · Glecaprevir/pibrentasvir Exposure Shows 51.7% Live Birth Rate in Study

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

More on this

  • Velamentous Cord Insertion: Prenatal Diagnosis and Individualized Delivery Planning in a Primigravida with Cardiac Comorbidity
  • Improved Blood Test Matches Spinal Fluid Accuracy for Alzheimer’s, Study Finds
  • EU Council Approves Trade and Investment Deals With Indonesia (archyde.com)

Related

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service